Kymera appoints Leigh Morgan to Board of Directors and Compensation Committee

Kymera Therapeutics, Inc.

Leigh Morgan appointed as Class II director effective July 6, 2022; term expires at 2025 annual meeting.
Board determined she is independent under Nasdaq listing standards.
Ms. Morgan also appointed to Compensation Committee; committee now includes Morgan, Albers, Maraganore, Nicholson.
She will receive standard non-employee director compensation; no material transactions disclosed.
No changes to Audit or Nominating and Corporate Governance Committees.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Leigh Morgan

Director

KYMR · Kymera Therapeutics, Inc.

Effective: 2022-07-06
Filed: July 8, 2022, 7:59 PM ET

the Board appointed Leigh Morgan to join the Board, effective as of July 6, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Leigh Morgan was appointed as Director at Kymera Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Leigh Morgan to join the Board, effective as of July 6, 2022.

View on SEC.gov

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-190006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.